News
SNTI
0.3840
+2.35%
0.0088
Weekly Report: what happened at SNTI last week (0803-0807)?
Weekly Report · 3d ago
VOO vs VTI: Are You Owning the Wrong Vanguard ETF?
TipRanks · 08/06 13:58
Weekly Report: what happened at SNTI last week (0727-0731)?
Weekly Report · 08/03 09:23
Weekly Report: what happened at SNTI last week (0720-0724)?
Weekly Report · 07/27 09:24
Weekly Report: what happened at SNTI last week (0713-0717)?
Weekly Report · 07/20 09:23
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 07/16 17:05
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/15 17:05
Senti Bio announces transaction to spin off Gene-Circuit-enabled pipeline
TipRanks · 07/15 12:00
Senti Biosciences to spin off its gene-circuit pipeline
Seeking Alpha · 07/15 11:59
Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Celadon For Up To $60M In Milestone Payments Over Seven Years
Benzinga · 07/15 11:33
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™
Barchart · 07/15 06:30
Weekly Report: what happened at SNTI last week (0706-0710)?
Weekly Report · 07/13 09:23
Weekly Report: what happened at SNTI last week (0629-0703)?
Weekly Report · 07/06 09:25
Weekly Report: what happened at SNTI last week (0622-0626)?
Weekly Report · 06/29 09:23
Weekly Report: what happened at SNTI last week (0615-0619)?
Weekly Report · 06/22 09:26
Weekly Report: what happened at SNTI last week (0608-0612)?
Weekly Report · 06/15 09:26
Weekly Report: what happened at SNTI last week (0601-0605)?
Weekly Report · 06/08 09:25
Weekly Report: what happened at SNTI last week (0525-0529)?
Weekly Report · 06/01 09:26
Senti Biosciences Details New Direct Financial Obligation
TipRanks · 05/26 21:05
Weekly Report: what happened at SNTI last week (0518-0522)?
Weekly Report · 05/25 09:27
More
Webull provides a variety of real-time SNTI stock news. You can receive the latest news about Senti Biosciences Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SNTI
Senti Biosciences Holdings, Inc. is a wholly owned subsidiary of Senti Holdings, Inc. Senti Biosciences, Inc. is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidate, SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers currently being studied in an open-label, multi-center Phase I clinical trial for the treatment of relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia.